



Opioid Technical Expert Panel (TEP) Web Meeting 3

The National Quality Forum (NQF) convened a public web meeting for the Opioid Technical Expert Panel on June 4, 2019.

Welcome, Introductions, and Review of Web Meeting Objectives

Poonam Bal, Senior Project Manager, NQF, welcomed participants to the web meeting and provided opening remarks. Vaishnavi Kosuri, Project Analyst, NQF, conducted roll call to determine Panel member participation. Ms. Bal conducted roll call for the federal liaisons on the call. Dr. Jeff Schiff and Dr. Brandon Marshall, the co-chairs of the Opioid TEP, also provided opening remarks. Ms. Bal then reviewed the meeting's objectives. This included an overview of the draft environmental scan, identification of current and potential measures, and requests for Panel feedback on the results of the environmental scan.

Overview of Environmental Scan Approach and Domains

Dr. Michael Abrams, Senior Director, NQF, provided an overview of the approach to the environmental scan and noted key questions for consideration by the Panel. These questions include consideration of existing measures, measure concepts, and gaps within the scope of the environmental scan. Dr. Abrams also provided an overview of the organizational domains discussed in Webinar 2. This overview included discussion of the prevention, substance use disorder (SUD) treatment, harm reduction and interdiction domains as well as ancillary issues such as alternative therapies or tobacco usage. Dr. Abrams noted that while the domains are not organized as a framework, they are provided to help sort the measures found by the environmental scan.

Environmental Scan Findings: Domains, Performance Measures, and Measure Concepts

Dr. Samuel Stolpe, Senior Director, NQF, presented the results of the draft environmental scan including an overview of the environmental scan process through a review of recent literature. Dr. Stolpe noted that after thorough review, 197 measures and 75 measure concepts were finalized. The pain management domain includes 124 measures and 41 measure concepts. This domain also includes types of measures addressing pain assessment, time to control, quality of life, pain care plan alternatives to opioids, and appropriate treatment. The treatment of opioid use disorder (OUD) domain has 56 measures and 26 measure concepts. The harm reduction domain has six measures and seven measure concepts. Finally, the social issues domain has three measures and one measure concept.

Dr. Schiff and Dr. Marshall prompted the Panel for discussion regarding the first domain in the environmental scan, pain management. The Panel noted several examples of measures and measure concepts such as shared decision making in pain management and pain care quality as gaps within the environmental scan. A Panel member also noted additional measures addressing self-efficacy, functional pain, and low back pain disability for inclusion within the appendix of

measures. Panel members provided input regarding balancing overprescribing with pain assessment measures. One Panel member supported the idea of balance and emphasized the need for measures addressing function, pain interferences, and multimodal treatment.

Dr. Schiff prompted the Panel to discuss the treatment of OUD, the second domain noted in the environmental scan. Panel members noted the importance of screening for comorbid conditions such as HIV or hepatitis for those who have already been diagnosed with OUD. In addition, the Panel noted an interest in OUD measures addressing the population of pregnant women. Finally, several members of the Panel noted an interest in a cascade of care or continuity while addressing OUD treatment.

Dr. Marshall elicited Panel discussion on the third domain called harm reduction. One Panel member noted the importance of interventions such as education, while others mentioned the need for syringe distribution, Narcan distribution, and provision of Fentanyl test strips. Dr. Schiff prompted the Panel to discuss social issues, the final domain of the environmental scan. The Panel noted a lack of longitudinal measures in this domain. One Panel member noted the impact of economic burden on patients regarding opioid usage, causing patients to use methamphetamines as an alternative. As such, Panel members supported the use of measures addressing social determinants of health to understand such burden.

Public Comment

Ms. Kosuri opened the web meeting to allow for public comment. One commenter from the Children's Hospital Association encouraged a strong focus on neonatal abstinence syndrome and maternal care related to opioid use and abuse issues.

Next Steps

Ms. Kosuri highlighted the 15-day comment period starting on July 12, 2019 for the environmental scan following the webinar. She then provided project contact information for any additional Panel input. Dr. Stolpe, Dr. Marshall, and Dr. Schiff provided closing remarks and adjourned the meeting.